Robert Coury - Mylan

Robert Coury - Mylan
Total Compensation: $21.3 million

Details: Coury took a bit of a pay cut in his final year as Mylan's ($MYL) chief after steady raises from 2008 to 2010. His base salary jumped by about $800,000 to $1.78 million, and he saw increases in stock awards and incentive compensation, but his deferred compensation dropped by more than $3 million.

Coury will stay on as executive chairman of the genericsmaker, which plans to broaden its sales by launching its own prescription drugs in India, and Mylan is optimistic that the $17.5 million it paid for Pfizer's dry powder inhaler technology will help the company carve out a space in the world respiratory market.

Robert Coury - Mylan

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.